Member Info for Zahrab4b

>1.52 for >1m shares.

Market maker bidding for large volume.

At this point, he would have to be very careful about how much he says about onshore.

Hence why he said nothing at all :-)

Lots clearly going on. Market cap was far higher pre-A3, and A3 found gas, plus Oba1 found gas. In addition, Etana progression has surprised to the upside. Nothing is reflected in the cap, which is down 70%. This will reverse soon.

Adonis seems pumped up.

Namibia will be secured soon.

Near-production and producing assets will be acquired in the next 12 months.

All will be funded via subsidiary level.

Existing holders will get a share in both businesses; two bites at the cherry.

At the current market cap, there could be huge gains from here.

Today’s strength in Chariot shares is no surprise.

With funding risk behind it, the focus can return to substantial near-term catalysts.

A revised Anchois development targeting 300 Bcf could generate over $500 million NPV10, deliver $150 million+ in annual free cash flow, and achieve payback in under 3 years.

Even a fraction of this potential justifies a valuation multiples higher than today’s $20 million market cap.

Https://find-and-update.company-information.service.gov.uk/company/15285671/filing-history

Completely turned. Leak?

Why is the BoD not doing anything to show progress on the key issues that are driving down the SP?

Silence is deafening

Thank you, Rebarm.

The ERF development is material to FDBK and should be updated via RNS. Can only assume TO is waiting to package this with ICB contract news.

Even with just 5 ICBs secured, that’s £10M in annual recurring revenue. With a clear roadmap to double that in the near term, the market could price in forward momentum — potentially valuing the company at £40–50M on a 4–5x forward revenue multiple. The Moorhouse partnership significantly de-risks delivery and scale, while the capital-light model supports strong operating leverage. Add the India opportunity and a pathway to broader NHS adoption, and you’ve got a highly scalable, strategic growth story

The stock has broken out of a well-formed falling wedge pattern, a classic bullish reversal signal.

Volume has surged during the breakout, confirming genuine buying interest.

Weekly candle strength above 17.5p indicates growing bullish sentiment and potential to test higher resistance levels in the 22–25p range.

Strengthening Fundamentals

Feedback has ~£7 million in cash, equating to almost its entire market cap, providing strong downside protection.

Recent strategic partnership with Moorhouse Consulting gives the company enhanced delivery capabilities for NHS contracts.

The Bleepa and DEAG solutions are well-positioned to meet NHS ICB digital diagnostics and patient flow needs.

With 42 ICBs across the UK and each contract estimated at ~£2 million annually, even a small number of successful deals could generate meaningful revenue uplift.

Undervalued and Under-the-Radar

At current prices, the stock trades near cash value, assigning minimal value to IP and growth potential.

If even a handful of ICBs onboard Feedback’s solution, revenue and profitability could inflect rapidly, driving a significant rerate.

Bleepa is already NHS-validated: It's live in NHS trusts, proven in real-world pilots, and winner of multiple awards.

The NHS knows who Feedback is — this is not an unknown player hoping for attention.

Now, the company is positioning itself for nationwide scale through not one, but two high-credibility partners:

1. Moorhouse Consulting – A heavyweight in NHS transformation, now working alongside Feedback to help navigate the ICB landscape and unlock multi-million-pound contracts.

2. Mystery Primary Care Partner – Likely a national player with a major footprint (think Boots, LloydsPharmacy, Well Pharmacy). Their reach can fast-track diagnostic services into the community – aligned perfectly with NHS policy.

Yes, partnering means revenue and margins will be shared, but it massively enhances execution credibility and scale potential. These are the partners you want if you're serious about becoming part of the NHS digital infrastructure.

Yet despite all this, the market has barely reacted.

Market cap ~£7m

Cash on hand ~£7m

Zero value assigned to the £382m/year diagnostics opportunity or NHS-wide ICB rollout

Speculation has to start soon. You now have a NHS-validated platform, a consulting giant guiding implementation, and a national infrastructure partner coming online.

This is what the start of large-scale healthcare adoption looks like.

Opportunity is gigantic.

Each ICB contract is worth £2M/year.

Feedback splits that with partner Moorhouse — so £1M ARR per contract.

There are 42 ICBs across the NHS. That’s a £42M/year opportunity just for FDBK’s share.

The market hasn’t priced this in — at all.

Right now:

Market Cap = £7M

Cash = £7M

Enterprise Value = £0 (yes, zero)

What happens if FDBK lands just 3 ICBs in Q2?

That’s £3M ARR to Feedback.

Apply a 5–10x SaaS multiple:

That’s 3–5x from here.

And that’s just 3 contracts.

Full rollout potential:

42 ICBs

£42M ARR

At 7x = £294M EV

Add £7M cash = £301M market cap

With 40M shares = £7.52/share

Yes — from sub-20p to £7.52 if they win it all.

Nobody’s paying attention — yet.

Zero enterprise value. Massive contract upside.

Once the first ICB wins land, the market will have to rerate this.

FDBK is a stealth re-rate in waiting.

Tom was explicit that ICBs were warmed up and multiple would be signing as soon as ERF was extended.

ICB contract news should be imminent. As FDBK trades at cash, multiple ICB contracts should be transformational from 17p.

Perhaps awaiting a major announcement to include contraxt news

Back to the 3s. With so much strength, I do believe 4s are incoming.

He must have a lot of mates!! Volume exploding

I like this suggestion

Maybe one more: Post well analysis indicates that the B sands thicknesses/ distribution / extent are better than feared and that a well in a slightly different location would probably confirm this. Jimmy’s guesstimate just after RNS was around 450bcf (total Anchois) I think so it may not take that much extra sands to get «North of 500bcf» being the minimum required subject to gas price of course.